The need for evidence-based documentation of the value story to overcome the ‘4th hurtle’ is prominent and payers are becoming sharper at distinguishing between recognizing true unmet need and potential cost savings through new and better medication. Documentation of increased value for money of a new drug is essential to achieve the desired price and reimbursement.
Example of a Pricing and Health Economical problem solved by Pharma Evidence:
Our client was interested in assessing the cost of not treating a given disease, and therefore asked Pharma Evidence to do the calculation.
First we performed a traditional cost of illness calculation based on daily, direct cost and additional lost productivity. Secondly, we examined registry data on the consequences of mal-diagnosis to calculate the additional cost to society.